by Touch Stone Publishers | Sep 23, 2026
The Signal Celldex Therapeutics filed an 8-K on September 22 disclosing that both Phase 3 EMBARQ-CSU trials of barzolvolimab met every primary and secondary endpoint at Week 12, with complete response rates above 42 percent against placebo rates near 10 percent....
by Touch Stone Publishers | Sep 16, 2026
Touch Stone Publishers | Sector Intel Daily | Healthcare | Priority 9 The Signal The post-subsidy ACA marketplace risk pool is running more profitable than the carriers that stayed in it priced for, and a second guidance raise in six weeks turns that from a quarter...
by Touch Stone Publishers | Aug 19, 2026
The Signal BioMarin has agreed to pay $275 million upfront and up to $215 million in development and regulatory milestones for Alesta Therapeutics, acquiring ALE1, an orally active small molecule in Phase 1/2a for hypophosphatasia. The 8-K filed August 18 states the...
by Touch Stone Publishers | Aug 5, 2026
The Signal Fitch Ratings split its 222-issuer nonprofit hospital and health system portfolio into three distinct credit trajectories ahead of OBBBA’s Medicaid reimbursement cuts, which begin phasing in during 2027. The agency’s 2026 sector outlook,...
by Touch Stone Publishers | Jul 29, 2026
The Signal The FDA’s own briefing document, released two days ahead of today’s advisory committee vote, states that Capricor Therapeutics’ pivotal trial for deramiocel failed both its primary and secondary efficacy endpoints, with no statistically...